TMT Acquisition Corporation priced its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “TMTCU” Tuesday, March 28, 2023.
The SPAC intends to focus its search on businesses that are operating in Asia and have a strong management team. TMT is led by CEO and Chairman Dajiang Guo, and CFO Jichuan Yang.
Total SPAC deal count for 2023 year-to-date is now 10. This offering is expected to close on Thursday, March 30, 2023.
Maxim Group LLC is acting as the sole book-running manager for the offering. Revere Securities LLC is acting as a co-manager for the offering. The Crone Law Group P.C. is serving as Issuer’s Counsel with Loeb & Loeb LLP serving as Underwriter’s Counsel. UHY LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
Graf Acquisition Corp. IV (NYSE:GFOR) announced in an 8-K this afternoon that it has come to a forward purchase agreement (FPA) with Meteora Capital Partners involving up to 2,500,000 shares for its combination with NKGen Biotech. Meteora is to purchase up to that amount on the open market prior to close, capped at 9.9% of...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Heard on the Street: VinFast’s SPAC Backers Are Backing Out Even by the standards of electric-vehicle startups, the $40 billion market value of Vietnamese electric-vehicle startup VinFast is wild, following its combination with Black Spade last month....
Murphy Canyon (NASDAQ:MURF) announced this morning that it has closed its combination with Conduit Pharmaceuticals and its shares and warrants are expected to begin trading on the Nasdaq under the symbols “CDT” and “CDTTW” on September 25. The company also closed a purchase of $20 million in Murphy Canyon units at close, which is to...
Indie Semiconductor (NASDAQ:INDI), which merged with Thunder Bridge II in June 2021, announced this morning that it has launched an exchange offer to convert each outstanding warrant to 0.285 Class A shares in the company. At Indie’s last closing price of $6.22, this is $1.77 of value each, although the stock has been rising since...
Atlantic Coastal II (NASDAQ:ACAB) has entered into a definitive agreement to combine with drug developer Abpro at a valuation of $725 million. Woburn, Massachusetts-based Abpro is advancing a series of drug candidates to potentially treat COVID, cancer and diabetic blindness. The combined company is expected to trade on the Nasdaq once the deal is completed...